Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Nathan Fowler, Fredrick B. Hagemeister, Chelsea C. Pinnix, Jason R. Westin, Francesco Turturro, Jennifer C. Ho, Sattva S. Neelapu, Jay Reddy, Lijuan Deng, Bouthaina S. Dabaja, Grace L. Smith, Ali Mazloom, T.Y. Andraos, Luis Fayad, Pamela K. Allen, Ken H. Young, Maria Alma Rodriguez, Loretta J. Nastoupil, Sarah A. Milgrom, Yasuhiro Oki, L. Jeffrey Medeiros, Wenli Dong
Publikováno v:
Leukemia & Lymphoma. 58:2833-2844
In 120 Stage I–IV testicular diffuse large B-cell lymphoma (DLBCL) patients treated from 1964 to 2015, we assessed the benefits of prophylactic contralateral testicular radiation (RT) and prophylactic central nervous system (CNS) therapy on overall
Autor:
Michael Wang, Nathan Fowler, Yasuhiro Oki, Francesco Turturro, Fredrick B. Hagemeister, Sattva S. Neelapu, Luis Fayad, Jason R. Westin, Jorge E. Romaguera, Hun J. Lee, Richard E. Davis, Loretta J. Nastoupil, Michelle A. Fanale, M. Alma Rodriguez, Dai Chihara, Felipe Samaniego, Bryan Do, Mohamed A. Ahmed
Publikováno v:
Cancer. 122:3145-3151
BACKGROUND The number of elderly patients with diffuse large B-cell lymphoma (DLBCL) in our aging society continues to rise, although the optimal management of very elderly patients with DLBCL is unknown. METHODS This study evaluated 207 patients who
Autor:
Loretta J. Nastoupil, Christopher R. Flowers, Jessica N. Williams, Jean L. Koff, Ashish Rai, Joseph Lipscomb
Publikováno v:
Cancer. 121:1800-1808
BACKGROUND Although the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is considered standard therapy for diffuse large B-cell lymphoma (DLBCL), patterns of use and the impact of R-CHOP on survival in pa
Autor:
Sarah A. Milgrom, Bouthaina S. Dabaja, Yasuhiro Oki, Jason R. Westin, Sattva S. Neelapu, Dai Chihara, Chelsea C. Pinnix, T.Y. Andraos, M. Alma Rodriguez, Andrea K. Ng, Grace L. Smith, Loretta J. Nastoupil, Luis Fayad
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 2, Iss 3, Pp 370-380 (2017)
Advances in Radiation Oncology, Vol 2, Iss 3, Pp 370-380 (2017)
Purpose The population of patients aged 80 years or older who are diagnosed with diffuse large B-cell lymphoma (DLBCL) continues to increase, but an optimal treatment strategy has not been established. We sought to examine the influence of consolidat
Autor:
Kun Jiang, Xiaojing Wang, Satya Das, Mohammad K. Khan, Christopher R. Flowers, Zheng Shi, Natia Esiashvili, Zhengjia Chen, Derick Okwan-Duodu, Loretta J. Nastoupil
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 86:569-577
The role of consolidative radiation therapy (RT) after complete response (CR) to rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for stage III-IV diffuse large B-cell lymphoma (DLBCL) patients is unclear. W
Autor:
Jessica N. Williams, Jean L. Koff, Loretta J. Nastoupil, Joseph Lipscomb, Ashish Rai, Christopher R. Flowers
Context: Despite having the highest incidence of diffuse large B-cell lymphoma (DLBCL), individuals older than 80 years are rarely included in DLBCL clinical trials or epidemiological studies. We sought to better characterize DLBCL presentation, trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fee4424f0ed48669cd5b02edd51ac83
https://europepmc.org/articles/PMC4441579/
https://europepmc.org/articles/PMC4441579/
Autor:
Andre Goy, Eric P. Winer, Rajneesh Nath, Chadi Nabhan, Ted Feldman, Andrew M. Evens, Aimee R. Kroll-Desrosiers, Frederick Lansigan, Deepa Jagadeesh, Lori Muffly, Loretta J. Nastoupil, Christopher R. Flowers, Bruce A. Woda, Jorge J. Castillo, Sonali M. Smith, Jeremy S. Abramson, Steve Rosen
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 25(11)
Optimal frontline therapy for peripheral T-cell lymphoma (PTCL) in the modern era remains unclear.We examined patient characteristics, treatment, and outcomes among 341 newly diagnosed PTCL patients from 2000 to 2011. Outcome was compared with a matc
Autor:
Timothy J. McDonnell, Sattva S. Neelapu, Kristin A. Simar, Francesco Turturro, Luis Fayad, Eric Davis, Vishwanath Sathyanarayanan, Fredrick B. Hagemeister, Ken H. Young, Fazal Kamil, Lei Feng, Loretta J. Nastoupil, Hubert H. Chuang, Yasuhiro Oki, Jason R. Westin
Publikováno v:
Blood. 128:5395-5395
Introduction: Diffuse large B-cell Lymphoma (DLBCL) is the most common lymphoid cancer in the United States with 30K diagnoses each year. The standard therapy for all newly diagnosed patients is rituximab, cyclophosphamide, doxorubicin, vincristine,
Autor:
Stacey A. Fedewa, Otis W. Brawley, Loretta J. Nastoupil, Joseph Lipscomb, Elizabeth Ward, Amy Y. Chen, Christopher R. Flowers
Publikováno v:
Cancer epidemiology, biomarkersprevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 21(9)
Background: Since the 1970s, CHOP chemotherapy has been the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL). In 2002, randomized trials changed this standard by showing that adding rituximab immunotherapy to CHOP improved s
Autor:
Richard E. Davis, Jason R. Westin, Luis Fayad, Alma Rodriguez, Mohamed Amin Ahmed, Loretta J. Nastoupil, Fredrick B. Hagemeister, Mansoor Noorani, Yasuhiro Oki
Publikováno v:
Blood. 126:3965-3965
Background: Effective and safe treatment approaches are needed for diffuse large B-cell lymphoma (DLBCL) in the elderly. One approach is to substitute a chemotherapeutic agent with liposomal formulation, expecting greater anti-tumor activity and less